The “typical patient” who requires standard therapies does not exist, according to contemporary research, which highlights the necessity for more specialised methods of managing unique clinical profiles as opposed to general diagnosis. In this regard, precision psychiatry has emerged, focusing on improving clinical subgroup identification, personalised evidence-based intervention suggestions, evaluation of the efficacy of various interventions, and identification of risk and protective factors for remission, relapse, and vulnerability. Numerous potential causes of depression have been postulated, and a number of elements, such as neural circuitry, biotypes, biopsychosocial indicators, genetics, and metabolomics, have been found to explain individual variations in pathology and response to therapy. Despite the precision approach’s potential to improve diagnosis and treatment choices, many obstacles are impeding its clinical adoption.In addition to ethical issues like safeguarding the confidentiality and security of patient data and preserving health equity, these include the clinical diversity of mental disorders, the complexities and costs of multiomics data, and the requirement for specialised training in precision health for medical practitioners.